Archives
-
Calnexin, CFTR Variants, and Corrector Rescue
2026-09-28
Tedman et al. used deep mutational scanning to show that the ER chaperone calnexin shapes CFTR surface expression and corrector responsiveness in a variant- and domain-dependent manner. The study separates proteostatic rescue from channel function, offering a stronger framework for interpreting genotype-specific responses in cystic fibrosis research.
-
ACT-III: Vernakalant for Rapid AF Conversion
2026-09-28
The ACT-III randomized trial found that intravenous vernakalant converted short-duration atrial fibrillation to sinus rhythm more often than placebo, with a median conversion time of eight minutes among responders. Its design and results support a rapid-conversion role for RSD1235 in selected patients, while the trial’s eligibility criteria and serious adverse event highlight the importance of patient selection and safety assessment.
-
EZ Cap™ Cas9 mRNA (m1Ψ): Editing Workflow
2026-09-27
A practical guide to using Cap1-capped, m1Ψ-modified Cas9 mRNA with guide RNA for mammalian-cell editing studies. Learn how to plan a small delivery pilot, separate product specifications from starting recommendations, and troubleshoot expression, viability, and editing readouts.
-
Protease Inhibitor Cocktail for Mbd5 Workflows
2026-09-26
Protect Mbd5-associated proteins during lysate preparation for co-immunoprecipitation, pull-downs, and immunoblotting without adding EDTA that can disrupt divalent-cation-sensitive assays. This practical guide connects the zebrafish Mbd5 study to sample handling choices—and explains when a protease cocktail alone is not enough.
-
EZ Cap™ Cas9 mRNA (m1Ψ) for Editing Workflows
2026-09-25
Explore how Cap1-capped, m1Ψ-modified Cas9 mRNA can support CRISPR experiments in mammalian cells and mouse zygotes. The workflow combines evidence from a zygote electroporation study with practical handling, delivery optimization, and troubleshooting guidance—while clearly distinguishing published conditions from starting-point recommendations.
-
Necrostatin-1 for RIP1 Kinase Workflows
2026-09-25
Use Necrostatin-1 to test whether RIP1 kinase activity contributes to stimulus-driven cell death, with a reported 30 µM, 24-hour condition as a practical benchmark. The workflow also shows how to investigate necrosis in host–parasite experiments without treating the reference study’s findings as proof of RIP1 involvement.
-
Sodium Overload Disrupts Mitochondrial Energy in NECSO
2026-09-24
Qiao and colleagues identify mitochondrial energy failure as a mechanism linking TRPM4-mediated sodium entry to necrosis in NECSO. Their findings connect increased mitochondrial sodium and reduced mitochondrial calcium with impaired oxidative phosphorylation and TCA-cycle activity, ATP depletion, and eventual failure of ion homeostasis.
-
Hypoxia duration shapes urothelial inflammasome activation
2026-09-24
A rat urothelial cell study found that short enzyme-induced hypoxia stabilized HIF-1α and increased nitric oxide activity without a detectable caspase-1 response, whereas longer exposure increased intracellular caspase-1. Attenuation by glutathione and verapamil supports a ROS/TXNIP-linked inflammatory mechanism, while the in vitro design leaves important questions about pathway specificity and bladder-level transferability.
-
CDK9 inhibitor A3294: Practical Lab Guide
2026-09-23
CDK9 inhibitor A3294 is a selective tool for probing CDK9-dependent transcription elongation and P-TEFb activity, with product-reported biochemical potency and HIV-1 assay findings. Use it for focused CDK9 experiments, not as a broad-spectrum CDK inhibitor or as evidence of general cytotoxic activity.
-
DNMT3B and Neuroendocrine Plasticity in Prostate Cancer
2026-09-23
The reference study identifies DNMT3B as a functional regulator of therapy-associated neuroendocrine and stemness programs in prostate cancer. Genetic or pharmacologic DNMT3B inhibition reduced neuroendocrine prostate cancer growth and altered lineage-associated markers, supporting DNMT3B as a mechanistically relevant target for treatment-resistant disease.
-
Antiepileptic Drugs and Human PON1 Inhibition
2026-09-22
The reference study established a comparative in vitro framework for testing five antiepileptic drugs against purified human serum paraoxonase-1 (hPON1). It found concentration-dependent, noncompetitive inhibition for every compound, with phenytoin showing intermediate inhibitory strength, providing biochemical context for drug–enzyme interactions beyond its established neuronal pharmacology.
-
VX-661: Rethinking F508del CFTR Rescue
2026-09-22
VX-661 is more than a trafficking rescue reagent: it is a platform for studying how CFTR folding, calnexin-dependent quality control, variant biology, and potentiator timing shape translational outcomes in cystic fibrosis research.
-
Acetylcysteine for Reliable Cell Assays
2026-09-21
This scenario-based guide explains how Acetylcysteine, SKU A8356, can support reproducible cell viability and oxidative-stress experiments. It covers assay interpretation, concentration selection, controls, literature context, and practical vendor-selection criteria.
-
Tetrahydromagnolol: CB2 Assay Workflows
2026-09-21
Tetrahydromagnolol supports receptor-first cannabinoid research, with a reported CB2 activation profile and complementary GPR55 antagonism. This guide translates those properties into practical assay workflows, controls, troubleshooting steps, and a carefully bounded extension into GPCR-driven cancer cell motility research.
-
Dual Recombinase Tracing and Mouse Neo-Oogenesis
2026-09-20
Xie, Zhou, and Zheng developed a dual-recombinase lineage-tracing strategy to test whether ovarian cells generate new oocytes after birth. Across physiological aging and busulfan-induced ovarian injury, the study found no evidence that postnatal non-germ-cell populations produced growing oocytes or metaphase II eggs, strengthening the case against in vivo neo-oogenesis in mice.